EFRUZHU  19/9

INFECTIONS  IN THE  CANCER  PATIENTS

​

®©

​

​

​

1.CANCER PATIENT IMMUNOSUPPRESSION DEGREE  RELATED  DIRECTLY  PROPORTIONAL OF INFECTIONS  DEGREE.

​

2.ALL OF THE ANTIBACTERIAL  AGENTS  PROPHYLAXIA /TREATMENT  RATIO  RELATED  INVERSELY PROPORTIONAL OF INFECTIONS  RESISTENCE.

​

3.MULTIPLE  PATHOGENICS  AGENTS NEED TO MULTIPLE  ANTIPATHOGENICS  COMPOUNDS.

​

4.INFECTIONS RESISTENCE STRATEGIES ESPECIALLY NEED TO  CONVENTIONAL  AND LAST GENERATIONS  DRUGS.

​

5.MONOTHERAPY AND COMBINED THERAPY  REGULATORY  APPLICATION SHOULD BE REDUCED OF INFECTION RESISTENCE.

​

6.INFECTIONS IN THE CANCER PATIENTS  PREVENTIONS  AND THERAPEUTIC  APPLICATIONS  SHOULD BE COOPERATED HUMORAL  AND  CELLULAR  SUPPORTIVE/PALLIATIVE  CARE  TOGETHER.

​

7.CANCER PATIENTS  PRIMER  PREVENTION  SYSTEM  STABILITY/UNSTABILITY RATIO RELATED   DIRECTLY   INFECTION DEGREE.

​

8.INFECTIOUS OF CANCER PATIENTS WITH NEUTROPENIA  COUNTS  AND EFFECTIVE  ACTIVITY  DEPENDENT OF  CELLULAR  AND HUMORAL IMMUN SYSTEM ABNORMALITY.

​

9.CHEMOTHERAPY. AND TUMORIGENIC  PATHOPHYSIOLOGIC   RELATED DIRECTLY  OR INDIRECTLY  OF IMMUNOSUPPRESSION 

​

10.NEUTROPENIA  OF CANCER PATIENTS  RESPECTIVELY   NEUTROPHIL  COUNTS 1000/500/100/50 MM3  RELATED  DIRECTLY  IMMUNOSUPPRESSION DEGREE.

​

11.NEUTROPENIC   TIME  INTERVAL  SHOULD BE EXPRESSED  FOUR  CATAGORIES 

0-3 / 3-7 / 7-14 / 14 DAYS AND MORE FOR CANCER 

PATIENTS,

​

12.INFECTION OF CANCER PATIENTS RISK ASSESMENT  RISK EVALUATION  SHOULD BE CLASSIFIED AS  4  CATAGORIES:LOW RISK / MODERATE RISK / HIGH RISK /  SEVERE  RISK   (MUCH HIGHER  RISK).